mg/mL. Samples from the 2-and 4-mg/mL admixtures were diluted into the range of the standard curve before injection into the HPLC system. After every 12th sample, an external standard of carboplatin 1 mg/mL was assayed; the within-day and betweenday coefficients of variation were <2.5%.
The assay was shown to be stability indicating by forcing the degradation of carboplatin. A sample of carboplatin 1 mg/mL was incubated at 70 °C for 24 hours. A second sample was stored at 4 °C as a control. After 24 hours, both samples were brought to ambient temperature, diluted, and assayed. The peak area for carboplatin after heating was 17% smaller than the peak area for the control solution. No peaks interfered with the peak for carboplatin.
Stability was defined as less than a 10% change from the actual initial concentration.
There was no visual evi-
Stability of carboplatin in polyvinyl chloride bags
he therapeutic index of carboplatin, an antitumor agent, may be improved if the drug is administered by continuous infusion rather than as i.v. bolus injections. 1 The manufacturer, however, recommends that admixtures of carboplatin be used within 24 hours if stored at 4 °C and within 8 hours if at room temperature. These limits are probably related more to microbiological safety (the solutions are preservative free) than drug stability. The objective of our study was to determine the compatibility and stability of carboplatin at concentrations and in containers used in our clinical protocols.
Commercially available carboplatin vials, 450 and 150 mg/mL, a were used to prepare admixtures of 0.5, 0.75, 2, and 4 mg/mL in polyvinyl chloride bags containing 100 mL of 5% dextrose injection. b Each T admixture was prepared under aseptic conditions. Because carboplatin in the presence of chloride ions may convert to cisplatin, 2 we studied the stability of carboplatin in a dextrose solution only.
Two admixtures of carboplatin at each concentration were stored at 4 °C, and a duplicate set was stored at 25 °C. All the admixtures were protected from light because light can affect carboplatin's stability. 2 Immediately after preparation and at 1, 3, 5, and 7 days (and, for the 0.5-and 4-mg/mL admixtures, 14 and 21 days), a 1-mL portion was removed from each container and assayed in triplicate.
Solutions were visually examined at each sampling time for precipitation (by inspection against black and white backgrounds) and discoloration. Solution pH was also measured.
Carboplatin concentra-tion was determined by using a modified version of the high-performance liquid chromatographic (HPLC) assay developed by Cheung et al. 2 Separation was achieved with an isocratic solvent delivery system c and C 18 column. d Before use, the mobile phase was degassed by ultrasound.
A variable-wavelength ultraviolet light detector e with wavelength set at 210 nm and sensitivity set at 0.1 absorbance unit full-scale, an integrator, f and an injector g were used for all determinations. The injection volume was 20 µL, and the flow rate was 1 mL/min. All reagents were HPLC grade. Analytical-grade carboplatin h was dissolved in deionized distilled water to prepare a 10-mg/mL stock solution, which was diluted with deionized distilled water to concentrations of 0.2-1.4 mg/mL. Each standard solution was assayed in triplicate. Linear regression of carboplatin peak area versus concentration generated a standard curve that was linear (r = 0.998) over the range of 0. . The mean ± S.D. actual initial concentrations of the samples from admixtures stored at 4 °C were 0.50 ± 0.007, 0.75 ± 0.004, 2.00 ± 0.008, and 4.00 ± 0.001 mg/mL and, from the admixtures stored at 25 °C, were 0.50 ± 0.0003, 0.75 ± 0.004, 2.00 ± 0.003, and 4.00 ± 0.009 mg/mL. b S.D. < 0.05%. c Samples were not taken for this study condition.
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dence of precipitation or color change in any of the carboplatin solutions. The pH of the solutions was unchanged (4.6-4.7) during storage.
The mean percentage of the initial carboplatin concentration remaining on day 7 was 99.3-102.8% for all the concentrations tested (table) . Carboplatin admixtures of 0.5 and 4 mg/ mL retained a mean of 94.7-100.3% of initial concentration on day 21. No differences were apparent among the concentrations analyzed. These results suggest that the stability of carboplatin does not depend on its initial concentration.
Our results agree with those of previous studies of the stability of carboplatin. 3, 4 Admixtures of carboplatin can be stored for periods longer than that stated by the manufacturer.
We presented the results of our study at the 1995 International Symposium of Oncology Pharmacy Practice in Hamburg, Germany. 
